Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer

Annals of the New York Academy of Sciences

Volumn 963, Issue , 2002, Pages 104-115

  Nicholson, R I ^a   Hutcheson, I R ^a   Harper, M E ^a   Knowlden, J M ^a   Barrow, D ^a   McClelland, R A ^a   Jones, H E ^a   Wakeling, A E ^b   Gee, J M W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; Estrogen receptor; Tyrosine kinase inhibitor; ZD 1839

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER HORMONE THERAPY; CELL GROWTH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; ESTROGEN RESPONSIVE ELEMENT; GROWTH REGULATION; HORMONE RELEASE; HUMAN; IN VITRO STUDY; ONCOGENE C ERB; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 0036295586     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04101.x     Document Type: Conference Paper

References (75)

1. New anti-hormonal approaches to breast cancer therapy
2. Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
3. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: Alterations of growth factor receptor binding sites and tyrosine kinase activity
4. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-1R) signalling pathway in breast cancer cells
5. Function of the IGF-1 receptor in breast cancer
6. Inhibition of c-erbB2 oncogene expression by oestrogens in human breast cancer cells
7. Mechanisms of EGF receptor regulation in breast cancer cells
8. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells
9. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells
10. Enhanced epidermal growth factor receptor signalling in MCF-7 breast cancer cells after long-term culture in the presence of the pure antioestrogen ICI 182780 (Faslodex)
11. Relationship between EGF-R, c-erbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity
12. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy
13. Transforming growth factor-alpha and endocrine sensitivity in breast cancer
14. erbB signalling in clinical breast cancer: Relationship to endocrine sensitivity
15. Phosphorylation of erk 1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer
16. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance
17. Processing of insulin-like growth factor-II (IGF-II) by human breast cancer cells
18. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: A comparison of the effects of cyclic adenosine 3′, 5′-monophosphate, estradiol, insulin-like growth factor-I, and serum factors
19. Cross-talk between peptide growth factor and estrogen receptor signaling pathways
20. Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression
21. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint
22. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells
23. Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells
24. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosinemonophosphate, and insulin-like growth factor-I
25. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
26. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus
27. Clinical response and resistance to SERMS
28. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components
29. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients
30. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue
31. Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer
32. A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines
33. Estrogen suppression of erbB2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro and in nude mice
34. Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells
35. Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896
36. Predictors of response to second-line endocrine therapy for breast cancer
37. A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo
38. The effects of a constitutive expression of transforming growth factor-alpha on the growth of MCF-7 human breast cancer cells in vitro and in vivo
39. Over-expression of the epidermal growth factor receptor in human breast cancer cells fails to induce an estrogen-independent phenotype
40. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells
41. Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations
42. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
43. Emergence of MCF-7 cells over-expressing a transfected epidermal growth factor receptor (EGFR) under estrogen-depleted conditions: Evidence for a role of EGFR in breast cancer growth and progression
44. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
45. Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: The effect of steroid hormones on insulin-like growth factor I receptor expression
46. Inhibition of HER/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-over-expressing, tamoxifen resistant breast cancer cells
47. New insights into the control of MAP kinase pathways
48. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells
49. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
50. Cellular effects of tamoxifen in primary breast cancer
51. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors
52. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue
53. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover
54. Resistance of human breast cancer cells to the pure steroidal anti-estrogen ICI 182780 is not associated with a general loss of estrogen receptor expression or lack of estrogen responsiveness
55. Epidermal growth factor receptors on human breast cancers
56. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
57. Over-expression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
58. Oestrogen receptor: A stable phenotype in breast cancer
59. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145
60. Effect of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: Identification of divergent growth regulatory pathways
61. ZD1839 ("Iressa") as an anticancer agent
62. Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
63. ZD 1839 Iressa
64. Inhibition of EGF receptor tyrosine kinase activity by 4-aniloquinazolines
65. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-aniloquinazolines
66. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
67. Clinical trials of Herceptin (trastuzumab)
68. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2